*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

**Simcere Pharmaceutical Group Limited**
**先聲藥業集團有限公司**
*(Incorporated in Hong Kong with limited liability)*
**(Stock code: 2096)**

# VOLUNTARY ANNOUNCEMENT

# THE CLINICAL TRIAL APPROVAL FOR SIM0610 (EGFR/cMET BISPECIFIC ANTIBODY-DRUG CONJUGATE) ISSUED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION

This announcement is made by Simcere Pharmaceutical Group Limited (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform shareholders and potential investors of the Company regarding the latest business development of the Group.

The board (the "**Board**") of directors (the "**Directors**") of the Company is pleased to announce that, he Group's independently developed Bispecific Antibody-Drug Conjugate ("**BsADC**") investigational new drug candidate, SIM0610, has received the Clinical Trial Approval issued by the National Medical Products Administration (國家藥品監督管理局) of China, and is intended to be evaluated in patients with locally advanced or metastatic solid tumors.

## ABOUT SIM0610

SIM0610 is a BsADC that simultaneously targets epidermal growth factor receptor ("**EGFR**") and mesenchymal-epithelial transition factor ("**cMET**"), and induces tumor cell apoptosis through intracellular release of a topoisomerase I inhibitor (TOP1i). EGFR and cMET are aberrantly activated in multiple solid tumors, including non-small cell lung cancer, and activation of the cMET pathway is one of the key mechanisms underlying resistance to EGFR tyrosine kinase inhibitors (EGFR-TKIs). Through dual-target synergistic activity, SIM0610 has the potential to enhance anti-tumor efficacy and overcome drug resistance. Preclinical studies have demonstrated that SIM0610 exhibits significant anti-tumor activity across multiple tumor models.

## ABOUT THE COMPANY

The Company is an innovation and R&D-driven pharmaceutical company and has established a "State Key Laboratory of Neurology and Oncology Drug Development". The Company focuses on the therapeutic areas of neuroscience, anti-oncology, autoimmune and anti-infection, with forward-looking layout of disease areas that may have significant clinical needs in the future, aiming to achieve the mission of "for patients, for life". Driven by its in-house R&D efforts and synergistic innovation, the Company has established strategic cooperation partnerships with many innovative companies and research institutes.

By order of the Board
**Simcere Pharmaceutical Group Limited**
**Mr. Ren Jinsheng**
*Chairman and Chief Executive Officer*

Hong Kong, December 23, 2025

*As at the date of this announcement, the Board comprises Mr. REN Jinsheng as the Chairman and executive Director; Mr. TANG Renhong, Mr. WAN Yushan and Ms. WANG Xi as the executive Directors; Mr. SONG Ruilin, Mr. WANG Jianguo, Mr. WANG Xinhua and Mr. SUNG Ka Woon as the independent non-executive Directors.*